Technology evaluation: edrecolomab, Centocor Inc.
Technology evaluation: edrecolomab, Centocor Inc.
复制标题
DOI：
--
复制
发表时间：
2000-10
影响因子：
--
通讯作者：
A. Abicht;Hanns Lochmüller
中科院分区：
文献类型：
--
作者：
A. Abicht;Hanns Lochmüller
Specific targeting of tumor cells may be achieved by using monoclonal antibodies to tumor antigens. Edrecolomab is a mouse-derived monoclonal IGg2A antibody directed against the human tumor-associated CO17-1A (or Ep-CAM) antigen, and is the first monoclonal antibody approved for cancer therapy. Encouraging results of several clinical trials were recently reported using edrecolomab for adjuvant therapy after surgery of Duke's C colorectal cancer. Side effects and toxicity profiles compare favorably to conventional regimens of radio- or chemotherapy. Future challenges lie in further improvement of these novel therapeutics, hopefully generating benefit for a larger number of cancer patients.
